Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 3
2010 1
2012 2
2013 1
2014 2
2015 3
2016 1
2017 3
2018 6
2019 5
2020 4
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J. Kauko O, et al. Among authors: sangodkar j. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. doi: 10.1126/scitranslmed.aaq1093. Sci Transl Med. 2018. PMID: 30021885 Free PMC article.
Therapeutic targeting of PP2A.
O'Connor CM, Perl A, Leonard D, Sangodkar J, Narla G. O'Connor CM, et al. Among authors: sangodkar j. Int J Biochem Cell Biol. 2018 Mar;96:182-193. doi: 10.1016/j.biocel.2017.10.008. Epub 2017 Oct 26. Int J Biochem Cell Biol. 2018. PMID: 29107183 Free PMC article. Review.
Targeting PP2A in cancer: Combination therapies.
Mazhar S, Taylor SE, Sangodkar J, Narla G. Mazhar S, et al. Among authors: sangodkar j. Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):51-63. doi: 10.1016/j.bbamcr.2018.08.020. Epub 2018 Sep 1. Biochim Biophys Acta Mol Cell Res. 2019. PMID: 30401535 Free PMC article. Review.
Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.
Rasool RU, O'Connor CM, Das CK, Alhusayan M, Verma BK, Islam S, Frohner IE, Deng Q, Mitchell-Velasquez E, Sangodkar J, Ahmed A, Linauer S, Mudrak I, Rainey J, Zawacki KP, Suhan TK, Callahan CG, Rebernick R, Natesan R, Siddiqui J, Sauter G, Thomas D, Wang S, Taylor DJ, Simon R, Cieslik M, Chinnaiyan AM, Busino L, Ogris E, Narla G, Asangani IA. Rasool RU, et al. Among authors: sangodkar j. Nat Commun. 2023 Aug 29;14(1):5253. doi: 10.1038/s41467-023-40760-6. Nat Commun. 2023. PMID: 37644036 Free PMC article.
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
Scarpa M, Singh P, Bailey CM, Lee JK, Kapoor S, Lapidus RG, Niyongere S, Sangodkar J, Wang Y, Perrotti D, Narla G, Baer MR. Scarpa M, et al. Among authors: sangodkar j. Mol Cancer Ther. 2021 Apr;20(4):676-690. doi: 10.1158/1535-7163.MCT-20-0663. Epub 2021 Feb 10. Mol Cancer Ther. 2021. PMID: 33568357 Free PMC article.
Reengineered tricyclic anti-cancer agents.
Kastrinsky DB, Sangodkar J, Zaware N, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M. Kastrinsky DB, et al. Among authors: sangodkar j. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34. doi: 10.1016/j.bmc.2015.07.007. Epub 2015 Sep 11. Bioorg Med Chem. 2015. PMID: 26372073 Free PMC article.
29 results